Client Spotlight: AutoIVF

About The Company

AutoIVF brings automation and precision engineering to one of medicine’s most delicate—and consequential—processes: in vitro fertilization. Despite decades of innovation in reproductive medicine, many IVF laboratory steps remain manual, leaving outcomes vulnerable to variability and the loss of fragile eggs during handling. AutoIVF is tackling this challenge head-on by introducing microfluidic automation that replaces manual pipetting with tightly controlled fluid dynamics, protecting eggs while improving consistency across IVF workflows.Founded by a multidisciplinary team of engineers and reproductive science experts, AutoIVF is building technology that brings modern process control to fertility labs. Its automated platform is designed to standardize critical laboratory steps, reduce variability between technicians and clinics, and help ensure that every viable egg is handled with the same level of precision. By applying advanced microfluidics and automation to reproductive medicine, AutoIVF aims to make IVF procedures more reliable, scalable, and accessible for clinics and patients around the world.

Recent scientific milestones have underscored both the urgency of the problem and the promise of AutoIVF’s solution. The company published a peer-reviewed study in Nature Medicine identifying a systematic source of egg loss in standard IVF workflows and evaluating an automated microfluidic approach to address it. Shortly afterward, the research and the technology behind it were featured in The New York Times in an article by Pulitzer Prize–winning journalist Pam Belluck—bringing national attention to a critical bottleneck in fertility treatment.

Together, these milestones represent rare, independent validation of both the clinical challenge and AutoIVF’s technical approach: rigorous scientific endorsement from one of the world’s leading medical journals, followed by broad recognition in a major national publication. As fertility treatments become increasingly important to families worldwide, AutoIVF is working to ensure the technology behind them is just as advanced—bringing automation, consistency, and engineering precision to a field where every cell matters.

Wolf Greenfield & AutoIVF

After AutoIVF licensed its foundational technology from Massachusetts General Hospital, the company turned to Wolf Greenfield around 2022 to help evaluate and strengthen its intellectual property position. The firm has worked closely with the team to assess the inherited patent portfolio, identify gaps in coverage, and recommend strategic filings to better protect the company’s automation technology for IVF workflows.

In parallel, Wolf Greenfield has advised AutoIVF on how to prioritize IP investments amid fundraising challenges, helping the company optimize protection while making the most effective use of limited resources. Through this collaboration, the firm has helped AutoIVF refine and reinforce the IP strategy supporting its innovative approach to improving IVF laboratory processes.